Francine Kaufman
Known title: Chief Medical OfficerCIK: 0001769791
Associated companies
Transaction History
| SENS | ▼ Sell | Tax Withholding | 4,010 | $29K | 6/15/2026 | View on chart |
| SENS | ▲ Buy | Grant | 63,177 | $0 | 5/19/2026 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 6,058 | $35K | 5/15/2026 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 4,605 | $29K | 11/15/2025 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 28,853 | $15K | 6/16/2025 | View on chart |
| SENS | ▲ Buy | Grant | 455,716 | $0 | 5/23/2025 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 101,587 | $56K | 5/15/2025 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 118,645 | $33K | 11/15/2024 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 64,722 | $25K | 6/15/2024 | View on chart |
| SENS | ▲ Buy | Grant | 1,024,270 | $0 | 5/23/2024 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 53,923 | $27K | 5/15/2024 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 115,908 | $71K | 11/15/2023 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 26,542 | $20K | 6/15/2023 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 128,877 | $95K | 5/15/2023 | View on chart |
| SENS | ▲ Buy | Grant | 429,382 | $0 | 5/15/2023 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 61,402 | $77K | 11/15/2022 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 6,352 | $6K | 6/15/2022 | View on chart |
| SENS | ▲ Buy | Grant | 150,863 | $0 | 5/26/2022 | View on chart |
| SENS | ▲ Buy | Grant | 50,000 | $0 | 5/26/2022 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 54,538 | $62K | 5/16/2022 | View on chart |
| SENS | ▼ Sell | Open Market | 163,870 | $403K | 2/11/2022 | View on chart |
| SENS | ▲ Buy | Grant | 310,884 | $0 | 2/10/2022 | View on chart |
| SENS | ▼ Sell | Open Market | 20,998 | $78K | 11/16/2021 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 55,531 | $211K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.